Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion [PDF]
, 2008 Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.Methods: A prospective, non-comparative ...
Alge, C. S. +9 more
core +1 more source
Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. [PDF]
, 2012 We describe the course and likely pathophysiology of impending anterior ischemic optic neuropathy (AION) and retinal vein occlusion in a 56-year-old man with polycythemia vera managed with interferon alpha for 2 years.
Hirsch, Louis K +2 more
core +1 more source
Molecular Analysis of Prothrombotic Gene Variants in Venous Thrombosis: A Potential Role for Sex and Thrombotic Localization [PDF]
, 2020 Background: Requests to test for thrombophilia in the clinical context are often not evidence-based. Aim: To define the role of a series of prothrombotic gene variants in a large population of patients with different venous thromboembolic diseases ...
AMATO, FELICE +9 more
core +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report a case with branch retinal vein occlusion secondary to a retinal astrocytic hamartoma in a patient with tuberous sclerosis complex.
Pedram Afshar +4 more
doaj +1 more source
Retrospective, controlled observational case study of patients with central retinal vein occlusion and initially low visual acuity treated with an intravitreal dexamethasone implant [PDF]
, 2016 Background Patients with initially low visual acuity were excluded from the therapy approval studies for retinal vein occlusion. But up to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than 34 ETDRS letters (
Annabelle Eckert +9 more
core +2 more sources
Managing retinal vein occlusion [PDF]
BMJ, 2012 #### Summary points Retinal vein occlusion—obstruction of the retinal venous system by thrombus formation, external compression, or disease of the vein wall1—is the second most common retinal vascular disease after diabetic retinopathy.2 Pooled data from population studies in the United States, Europe, Asia, and Australia suggest that about 16 million
Kiire, C, Chong, N
openaire +4 more sources
Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]
, 2012 Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos +7 more
core +1 more source
Branch Retinal Vein Occlusion [PDF]
The Journal of Clinical Hypertension, 2003 The most common cause of branch retinal vein occlusion is hypertension. Since retinal arteries and veins share a common adventitial sheath, the thickened artery compresses a retinal vein causing an occlusion, resulting in a retinal hemorrhage. Most patients present in their 60s with unilateral involvement. The patient may be asymptomatic if the macula
Milan R, Patel +2 more
openaire +2 more sources
F1000Research, 2018 Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care ...
Daniel D. Esmaili, David S. Boyer
doaj +1 more source
Widening use of dexamethasone implant for the treatment of macular edema [PDF]
, 2017 Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T. +9 more
core +2 more sources